Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2015

View Archived Issues

Adapt Pharma successfully completes pharmacokinetic study of intranasal naloxone

VolitionRx and Hvidovre Hospital initiate trial to identify NuQ biomarkers for colorectal polyps

Biohaven advancing BHV-0223 toward phase I trial

Enrollment open in phase II study of GI-6301 for chordoma

European CANCER-ID consortium formed to validate blood biomarkers of cancer

Shanghai De Novo Pharmatech characterizes AML candidate SC-110237

Clinical data reported for antibody-drug conjugate SGN-CD33A

ThromboGenics starts developing Jetrea for retinal vein occlusion

Janssen seeks Japanese approval of Risperdal for irritability in children with autistic disorder

Karus Therapeutics presents PI3Kbeta/delta inhibitors

U.S. orphan drug designation awarded to Dicerna's DCR-PH1 for primary hyperoxaluria type 1

Celgene and MedImmune collaborate to develop MEDI-4736 for hematologic malignancies

Bayer patents FXIa inhibitors

Bayer seeks Japanese approval for radium-223 dichloride

Janssen Pharmaceutica discloses NIK inhibitors

Cortendo reports development of novel cytochrome P450 inhibitors

Korean researchers present HRP-3 inhibitors

Roche divulges new tau-imaging compounds

FDA approves label update to Pomalyst

Aerie reports results from first registrational study of Rhopressa

FDA grants priority review to idarucizumab BLA

World Malaria Day: unveiling parasite resistance mechanisms

Actavis launches Avycaz in U.S.

AstraZeneca and Innate Pharma collaborate on development of IPH-2201

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...